COVID-19 vaccine developer Moderna (Nasdaq: MRNA) has reported first quarter 2022 revenues of $6.1 billion, more than triple the $1.7 billion for the same period of 2021, handily outpacing analysts’ expectations.
As in 2021, almost all of the money came from sales of the company's coronavirus vaccine, its only approved product.
The company is in for another game-changing year, with signed advance purchase agreements worth around $21 billion in place.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze